Abstract
Prostate cancer is the second most common cancer and the fifth most common cause of cancer deaths in men worldwide. Before docetaxel chemotherapy, no single agent demonstrated a survival advantage for men with metastatic castration resistant prostate cancer (mCRPC). However, 2010 has proven to be a landmark year for prostate cancer therapy, with the results of several phase III trials demonstrating improvements in survival with novel therapies. In this review, we examine promising front-line docetaxel combination therapies for chemotherapy naïve patients and novel cytotoxic chemotherapies for patients with progressive disease. We will also highlight a clinical trial utilizing a genome based approach to evaluate the efficacy of a fourth generation platinum, satraplatin, in patients with sporadic BRCA deficient prostate cancers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
